Table 2.

The clinical trials exploring the efficacy of α-PD-1/PD-L1 plus chemotherapy

Clinical trial	Phase	α-PD-1/PD-L1	Chemotherapy	Cancer type	Primary outcome measures
NCT02039674	1/2	Pembrolizumab	Pemetrexed and carboplatin	Non-squamous NSCLC	ORR
NCT02775435	3	Pembrolizumab	Paclitaxel/nab-paclitaxel and carboplatin	Squamous NSCLC	PFS, OS
NCT02819518	3	Pembrolizumab	Paclitaxel; nab-paclitaxel; gemcitabine and carboplatin	TNBC	PFS, OS
NCT03189719	3	Pembrolizumab	Cisplatin and 5-fluorouracil	Esophageal or GEJ cancer	PFS, OS
NCT03615326	3	Pembrolizumab	Trastuzumab plus either 5-fluorouracil plus cisplatin or capecitabine plus oxaliplatin	HER2+ gastric or GEJ adenocarcinoma	PFS, OS
NCT02872116	3	Nivolumab	5-fluorouracil and leucovorin plus oxaliplatin; capecitabine and oxaliplatin	Gastric cancer, esophageal or GEJ adenocarcinoma	PFS, OS
NCT03607539	3	Sintilimab	Pemetrexed and platinum	Non-squamous NSCLC	PFS
NCT03629925	3	Sintilimab	Gemcitabine and platinum	Squamous NSCLC	PFS
NCT03134872	3	Camrelizumab	Carboplatin and pemetrexed	Non-squamous NSCLC	PFS
NCT03707509	3	Camrelizumab	Gemcitabine and cisplatin	Nasopharyngeal carcinoma	PFS
NCT03594747	3	Tislelizumab	Paclitaxel/nab-paclitaxel and carboplatin	Squamous NSCLC	PFS
NCT03663205	3	Tislelizumab	Platinum and pemetrexed	Non-squamous NSCLC	PFS
NCT02366143	3	Atezolizumab	Bevacizumab plus paclitaxel and carboplatin	Non-squamous NSCLC	PFS, OS
NCT02763579	3	Atezolizumab	Carboplatin and etoposide	SCLC	PFS, OS
NCT02425891	3	Atezolizumab	Nab-paclitaxel	TNBC	PFS, OS
NCT02367781	3	Atezolizumab	Carboplatin and nab-paclitaxel	Non-squamous NSCLC	PFS, OS
NCT03043872	3	Durvalumab	Etoposide and carboplatin/ cisplatin	SCLC	OS

Abbreviations: NSCLC non-small cell lung cancer, ORR objective response rate, PFS progression-free survival, OS overall survival, GEJ gastroesophageal junction, SCLC small cell lung cancer